AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
MYLAN Dec-18 |
ASTRAZENECA PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 3,521 | - | |
Low | Rs | 883 | 1,938 | - | |
Sales per share (Unadj.) | Rs | 228.4 | 1,620.4 | - | |
Earnings per share (Unadj.) | Rs | 10.4 | 44.0 | - | |
Cash flow per share (Unadj.) | Rs | 16.3 | 347.4 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 98.8 | 1,752.9 | - | |
Shares outstanding (eoy) | m | 25.00 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 1.7 | 280.8% | |
Avg P/E ratio | x | 104.2 | 62.0 | 168.0% | |
P/CF ratio (eoy) | x | 66.4 | 7.9 | 845.5% | |
Price / Book Value ratio | x | 10.9 | 1.6 | 702.3% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 27,008 | 1,404,514 | 1.9% | |
No. of employees | `000 | 1.4 | 35.0 | 3.9% | |
Total wages/salary | Rs m | 1,535 | 0 | - | |
Avg. sales/employee | Rs Th | 4,210.9 | 23,819.4 | 17.7% | |
Avg. wages/employee | Rs Th | 1,132.2 | 0 | - | |
Avg. net profit/employee | Rs Th | 191.1 | 646.8 | 29.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 833,681 | 0.7% | |
Other income | Rs m | 123 | 0 | - | |
Total revenues | Rs m | 5,833 | 833,681 | 0.7% | |
Gross profit | Rs m | 463 | 215,726 | 0.2% | |
Depreciation | Rs m | 147 | 156,098 | 0.1% | |
Interest | Rs m | 0 | 40,097 | 0.0% | |
Profit before tax | Rs m | 438 | 19,531 | 2.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | -3,107 | -5.8% | |
Profit after tax | Rs m | 259 | 22,638 | 1.1% | |
Gross profit margin | % | 8.1 | 25.9 | 31.3% | |
Effective tax rate | % | 40.8 | -15.9 | -256.7% | |
Net profit margin | % | 4.5 | 2.7 | 167.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 465,527 | 0.7% | |
Current liabilities | Rs m | 2,070 | 339,420 | 0.6% | |
Net working cap to sales | % | 20.0 | 15.1 | 132.0% | |
Current ratio | x | 1.6 | 1.4 | 113.1% | |
Inventory Days | Days | 72 | 84 | 86.6% | |
Debtors Days | Days | 35 | 93 | 37.4% | |
Net fixed assets | Rs m | 790 | 161,720 | 0.5% | |
Share capital | Rs m | 50 | 444 | 11.3% | |
Net worth | Rs m | 2,469 | 901,890 | 0.3% | |
Long term debt | Rs m | 0 | 973,429 | 0.0% | |
Total assets | Rs m | 4,605 | 2,419,220 | 0.2% | |
Interest coverage | x | NM | 1.5 | - | |
Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.3 | 359.8% | |
Return on assets | % | 5.6 | 2.6 | 217.0% | |
Return on equity | % | 10.5 | 2.5 | 418.0% | |
Return on capital | % | 17.7 | 3.2 | 557.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 173,239 | 0.1% | |
From Investments | Rs m | -94 | -89,545 | 0.1% | |
From Financial Activity | Rs m | NA | -80,705 | 0.0% | |
Net Cashflow | Rs m | -6 | 1,435 | -0.4% |
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ASTRAZENECA PHARMA With: ALEMBIC TORRENT PHARMA PANACEA BIOTECH WOCKHARDT CADILA HEALTHCARE
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More